Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Letter from the Editor
If you look at studies from 40 years ago, there was always the mention of using insulin in type 2 patients. Then in the 90’s when glargine first came out, Sanofi worked hard to bring across the idea of resting the pancreas by starting their long acting insulin in type 2 patients.
As educators many of us have made the case of starting basal insulin sooner to save pancreatic beta cell function.
This week our intern, Taylor Simmons, brings us a presentation from Dr. Irl Hirsch providing even more compelling reasons to start insulin sooner.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
Current studies are showing that micro and macro complications begin at prediabetes.
The majority of patients with type 2 diabetes fail to maintain glycemic goals over time after initial success with standard interventions.
Overview of new technologies and their role, as well as challenges they bring.
Did You Know? Micro and Macro Complications Begin with Prediabetes
We have known that diabetes causes microvascular complications, but we are now seeing that in prediabetes, we see not only micro but also macrovascular complications.
The object of this current study, “Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population“ was to evaluate whether high glucose levels in the normoglycemic range and higher have a causal genetic effect on the risk of retinopathy, neuropathy, nephropathy, chronic kidney disease (CKD), peripheral arterial disease (PAD), and myocardial infarction (MI; positive control) in the general population. This study applied observational and one-sample Mendelian randomization (MR) analyses to individual-level data from 117,193 Danish individuals, and validation by two-sample MR analyses on summary-level data from 133,010 individuals from the Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC), 117,165 from the CKDGen Consortium, and 452,264 from the UK Biobank. The results showed that glucose levels in the normoglycemic range and higher were associated with high risks of retinopathy, neuropathy, diabetic nephropathy, PAD, and MI (all P for trend <0.001). In causal genetic analyses, the risk ratio for a one mmol/L higher glucose level was 2.01 (95% CI 1.18–3.41) for retinopathy, 2.15 (1.38–3.35) for neuropathy, 1.58 (1.04–2.40) for diabetic nephropathy, 0.97 (0.84–1.12) for estimated glomerular filtration rate (eGFR). More Info: See item 1 Diabetes Care 2020 Apr; 43(4): 894-902
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Antonio Bess, Pharm D Candidate, Florida Agricultural & Mechanical University School of Pharmacy
Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University School of Pharmacy
Alessa Grieff, PharmD Candidate, University of South Florida College of Pharmacy
Taylor-Eugene Simmons, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences, PharmD Candidate
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com